Physician profile
Leanna Marderian Wise
NPI 1881013548
$285,518.85
in general payments reported to CMS, 2019-2025
8 companies · $108K in 2025
The $108K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $25.13 · 2021: $22K · 2022: $33K · 2023: $47K · 2024: $75K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $33K · Consulting Fee: $23K · Food and Beverage: $7,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,117.50 |
| Travel and Lodging | $33,260.00 |
| Consulting Fee | $22,577.44 |
| Food and Beverage | $7,377.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $103,416.90 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $90,804.60 | 2022-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $90,719.29 | 2021-2025 | Lupkynis |
| Abbvie INC. | $277.04 | 2020-2024 | Rinvoq, Skyrizi |
| Amgen INC. | $171.94 | 2019-2024 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $97.14 | 2019 | |
| Argenx US, INC. | $31.94 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanna Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.